Psoriatic patients undergoing long‐term therapy with biologics: Impact of residual localization of psoriasis on quality of life in an Italian clinical setting

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Muhammad Ali Muslimani ◽  
Vittorio Bolcato ◽  
Annalisa Silvestri ◽  
Valeria Brazzelli
Keyword(s):  
Quality Of Life ◽  
Clinical Setting ◽  
Term Therapy ◽  
Long Term Therapy

Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy

2017 ◽  
Vol 21 (3) ◽  
pp. 565-569 ◽  
Author(s):  
Tanja Kraus ◽  
Kathrin Gegenleitner ◽  
Martin Svehlik ◽  
Michael Novak ◽  
Gerhardt Steinwender ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Intrathecal Baclofen ◽  
Spastic Cerebral Palsy ◽  
Term Therapy ◽  
Long Term Therapy

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Blood ◽  
2011 ◽  
Vol 118 (17) ◽  
pp. 4554-4560 ◽  
Author(s):  
Fabio Efficace ◽  
Michele Baccarani ◽  
Massimo Breccia ◽  
Giuliana Alimena ◽  
Gianantonio Rosti ◽  
...  
Keyword(s):  
Quality Of Life ◽  
General Population ◽  
Myeloid Leukemia ◽  
Term Therapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Long Term Therapy

Abstract The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.

scholarly journals Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis

2020 ◽  
Vol 9 (1) ◽  
pp. 154 ◽  
Author(s):  
Fabio Barra ◽  
Carolina Scala ◽  
Umberto Leone Roberti Maggiore ◽  
Simone Ferrero
Keyword(s):  
Quality Of Life ◽  
Oral Treatment ◽  
Fourth Generation ◽  
Term Therapy ◽  
Deep Endometriosis ◽  
Wide Range ◽  
Intestinal Symptoms ◽  
Long Term Therapy

Background: Rectosigmoid endometriosis is a severe form of deep endometriosis, which may be responsible for pain symptoms and a wide range of intestinal complains such as diarrhea, constipation, and abdominal cramping. The primary objective of this study was to evaluate the efficacy of long-term therapy with dienogest (DNG), a fourth-generation progestin, for ameliorating quality of life, pain, and intestinal symptoms of patients affected by rectosigmoid endometriosis. Methods: A retrospective analysis of a prospectively collected database was done on patients with endometriotic nodules infiltrating at least the muscular layer of the rectosigmoid wall with an estimated colorectal stenosis <60%. The diagnosis of rectosigmoid endometriosis was based on transvaginal ultrasonography. Patients accepting to participate in the study received continuous oral treatment with DNG at the dose of 2 mg/day. Results: At the end of the first year of treatment, a significant decrease in dysmenorrhea (P < 0.001), chronic pelvic pain (P < 0.001), dyspareunia (P < 0.001), dyschezia (P < 0.001), and in intestinal symptoms (P < 0.001) was observed. A progressive increase of the Endometriosis Health Profile-30 (EHP-30) and Gastrointestinal Quality of Life Index (GIQLI) scores was observed in the first two years of therapy (P < 0.001 and P < 0.001, respectively). Improvements of patients’ symptoms and quality of life were maintained until the end of the study. The regimen was well tolerated, and the frequency and amount of irregular bleeding decreased as treatment progressed. Conclusion: The current study confirms the efficacy of long-term therapy with DNG for treating symptoms caused by rectosigmoid endometriosis.

Improved quality of life in asthma patients under long-term therapy: Assessed by AHQ-Japan

2016 ◽  
Vol 71 (1) ◽  
pp. e12898 ◽  
Author(s):  
Yuji Tohda ◽  
Takashi Iwanaga ◽  
Hiroyuki Sano ◽  
Hiroaki Kume ◽  
Kazuto Hirata ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Term Therapy ◽  
Asthma Patients ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document